← Leaderboards
Thomas W Ferkol
Case Western Reserve University
$6,680,461
Attributed
$10,298,521
Total exposure
18
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$17,792,941 · 19
By mechanism
U54$7,883,208 · 2
R01$4,459,407 · 3
U01$2,139,391 · 1
T32$1,747,614 · 1
R21$844,524 · 2
P50$695,001 · 1
Top collaborators
- Stephanie Duggins Davis9 shared
- Robert P. Mecham6 shared
- Aaron Hamvas4 shared
- Sarath Chandra Ranganathan4 shared
- Gregory A. Storch2 shared
- Barbara B Warner1 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Andrew Resnick$1,532,689
- Tomoko Obara$1,645,911
- Pamela B Davis$114,848,546
- Shenandoah Robinson$4,458,648
- Rebecca J Darrah$1,952,701
Others in their field
Top investigators on “Chronic”
- Judith S. Currier · University Of California Los Angeles$245,012,139
- Lawrence Corey · Fred Hutchinson Cancer Center$209,947,290
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$201,828,077
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$173,476,538
- John M Lachin · George Washington University$125,152,883
- David M Nathan · Massachusetts Institute Of Technology$120,438,756
Research focus
ChronicPathogenesisLung DiseasesLungResearch PersonnelBaseMucociliary ClearanceInflammationClinical TrialsRespiratoryPrimary Ciliary DyskinesiasClinical ResearchDiagnosisBronchiectasisInsightCystic FibrosisNovel StrategiesProgramsRare DiseasesResourcesPhenotypePreventInheritedLink
Grant awards (49)
Genetic Disorders of Mucociliary Clearance$1,448,157
U54 · FY2023 · HL
Characterizing respiratory exacerbations in primary ciliary dyskinesia$231,393
R21 · FY2023 · TR · contact PI
GDMCC Pilot Feasibility$83,140
U54 · FY2023 · HL · contact PI
Genetic Disorders of Mucociliary Clearance$1,461,652
U54 · FY2022 · HL
Characterizing respiratory exacerbations in primary ciliary dyskinesia$196,875
R21 · FY2022 · TR · contact PI
GDMCC Pilot Feasibility$83,162
U54 · FY2022 · HL · contact PI
Genetic Disorders of Mucociliary Clearance$1,471,263
U54 · FY2021 · HL
GDMCC Pilot Feasibility$84,025
U54 · FY2021 · HL · contact PI
Genetic Disorders of Mucociliary Clearance$1,487,339
U54 · FY2020 · HL
GDMCC Pilot Feasibility$85,722
U54 · FY2020 · HL · contact PI
Genetic Disorders of Mucociliary Clearance$1,626,009
U54 · FY2019 · HL
Pediatric Cardiovascular and Pulmonary Research Training Program$289,806
T32 · FY2019 · HL
GDMCC Pilot Feasibility$52,739
U54 · FY2019 · HL · contact PI
Pediatric Cardiovascular and Pulmonary Research Training Program$377,915
T32 · FY2018 · HL
Pediatric Cardiovascular and Pulmonary Research Training Program$368,839
T32 · FY2017 · HL
Pediatric Cardiovascular and Pulmonary Research Training Program$1,944
T32 · FY2017 · HL
Pediatric Cardiovascular and Pulmonary Research Training Program$363,500
T32 · FY2016 · HL
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease$531,756
R01 · FY2015 · HL
Pediatric Cardiovascular and Pulmonary Research Training Program$345,610
T32 · FY2015 · HL
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease$530,129
R01 · FY2014 · HL
Influence of the Enteric Microbiome on the Genesis of Bronchopulmonary Dysplasia$493,598
U01 · FY2014 · HL · contact PI
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease$523,412
R01 · FY2013 · HL
Influence of the Enteric Microbiome on the Genesis of Bronchopulmonary Dysplasia$469,426
U01 · FY2013 · HL
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease$605,339
R01 · FY2012 · HL
Influence of the Enteric Microbiome on the Genesis of Bronchopulmonary Dysplasia$478,923
U01 · FY2012 · HL
Influence of the Enteric Microbiome on the Genesis of Bronchopulmonary Dysplasia$476,998
U01 · FY2011 · HL
Influence of the Enteric Microbiome on the Genesis of Bronchopulmonary Dysplasia$220,446
U01 · FY2010 · HL
Delivering antiproteases to the bronchiectatic airway$295,184
R01 · FY2009 · HL · contact PI
Delivering antiproteases to the bronchiectatic airway$295,184
R01 · FY2008 · HL · contact PI
Delivering antiproteases to the bronchiectatic airway$295,184
R01 · FY2007 · HL · contact PI
EPIC - 001, CLINICAL TRIAL$2,440
M01 · FY2007 · RR · contact PI
DIAGNOSTIC AND CLINICAL CHARACTERIZATION OF PATIENTS WITH UNUSUAL GENETIC DIS$1,627
M01 · FY2007 · RR · contact PI
TIOTROPIUM TRIAL # 205338$813
M01 · FY2007 · RR · contact PI
LONGITUDINAL STUDY OF PRIMARY CILIARY DYSKINESIA (PCD STUDY)$136
M01 · FY2007 · RR · contact PI
Delivering antiproteases to the bronchiectatic airway$305,000
R01 · FY2006 · HL · contact PI
Genetic variants of primary ciliary dyskinesia$186,756
R21 · FY2006 · HL · contact PI
AN ASSESSMENT OF INDUCED SPUTUM AS A TOOL TO EVALUATE ANTI-INFLAMMATORY AGENT$2,915
M01 · FY2006 · RR · contact PI
EPIC - 001, CLINICAL TRIAL$2,083
M01 · FY2006 · RR · contact PI
Genetic variants of primary ciliary dyskinesia$229,500
R21 · FY2005 · HL
THERACLEC-TOTAL IN CYSTIC FIBROSIS SUBJECTS WITH EXOCRINE PANCREATIC INSUFFICIEN$7,394
M01 · FY2005 · RR
PARALLEL DOSE RANGING STUDY OF THERCLEC TOTAL IN CF SUBJECTS WITH EXOCRINE$2,875
M01 · FY2005 · RR
Targeted Delivery of Interleukin-10$269,500
R01 · FY2004 · HL
Genetic Modifiers of Cystic Fibrosis$3,513
M01 · FY2004 · RR
Targeted Delivery of Interleukin-10$269,500
R01 · FY2003 · HL
Targeted Delivery of Interleukin-10$269,500
R01 · FY2002 · HL
TARGETING PROTEINS TO THE RESPIRATORY EPITHELIAL SURFACE$263,865
P50 · FY2002 · HL
Targeted Delivery of Interleukin-10$269,719
R01 · FY2001 · HL
TARGETING PROTEINS TO THE RESPIRATORY EPITHELIAL SURFACE$263,865
P50 · FY2001 · HL
TARGETING PROTEINS TO THE RESPIRATORY EPITHELIAL SURFACE$167,271
P50 · FY2000 · HL